Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older Patients

Real-world studies in the USA report that 41-56% of patients with multiple sclerosis (MS) are ≥ 50 years old, yet data on their response to disease-modifying therapies (DMTs) is limited. Dimethyl fumarate (DMF) is an oral DMT approved for treating relapsing MS. This analysis evaluated the safety, ef...

Full description

Saved in:
Bibliographic Details
Published in:Advances in therapy 2024-11
Main Authors: Mao-Draayer, Yang, Bar-Or, Amit, Balashov, Konstantin, Foley, John, Smoot, Kyle, Longbrake, Erin E, Robertson, Derrick, Mendoza, Jason P, Lewin, James B, Everage, Nicholas, Božin, Ivan, Lyons, Jennifer, Mokliatchouk, Oksana, Bame, Eris, Giuliani, Fabrizio
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Real-world studies in the USA report that 41-56% of patients with multiple sclerosis (MS) are ≥ 50 years old, yet data on their response to disease-modifying therapies (DMTs) is limited. Dimethyl fumarate (DMF) is an oral DMT approved for treating relapsing MS. This analysis evaluated the safety, efficacy, and immunophenotype changes of DMF in patients ≥ 50 years compared with patients
ISSN:0741-238X
1865-8652
1865-8652
DOI:10.1007/s12325-024-03047-w